{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:16:59Z","timestamp":1790864219747,"version":"4.1.0"},"reference-count":128,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1097\/hjh.0b013e32832810ed","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T13:09:43Z","timestamp":1242911383000},"page":"680-691","source":"Crossref","is-referenced-by-count":77,"title":["Aldosterone-receptor antagonism in hypertension"],"prefix":"10.1097","volume":"27","author":[{"given":"Pieter M","family":"Jansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AH Jan","family":"Danser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben P","family":"Imholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton H","family":"van den Meiracker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210208","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1210\/jc.2003-031337","article-title":"Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents","volume":"89","author":"Mulatero","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R2-2-20210208","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1440-1681.1993.tb01687.x","article-title":"Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers","volume":"20","author":"Gordon","year":"1993","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R3-2-20210208","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","article-title":"High incidence of primary aldosteronism in 199 patients referred with hypertension","volume":"21","author":"Gordon","year":"1994","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R4-2-20210208","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/sj.jhh.1001013","article-title":"High prevalence of primary aldosteronism in the Tayside hypertension clinic population","volume":"14","author":"Lim","year":"2000","journal-title":"J Hum Hypertens"},{"key":"R5-2-20210208","first-page":"1863","article-title":"Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology","volume":"85","author":"Fardella","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-2-20210208","first-page":"2854","article-title":"Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore","volume":"85","author":"Loh","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-2-20210208","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0272-6386(01)80117-7","article-title":"Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone\u2013renin ratio","volume":"37","author":"Gallay","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"R8-2-20210208","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0895-7061(02)02969-2","article-title":"High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives","volume":"15","author":"Rossi","year":"2002","journal-title":"Am J Hypertens"},{"key":"R9-2-20210208","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.jhh.1001554","article-title":"Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region","volume":"17","author":"Strauch","year":"2003","journal-title":"J Hum Hypertens"},{"key":"R10-2-20210208","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/00004872-200311000-00025","article-title":"High rate of detection of primary aldosteronism, including surgically treatable forms, after \u2018nonselective\u2019 screening of hypertensive patients","volume":"21","author":"Stowasser","year":"2003","journal-title":"J Hypertens"},{"key":"R11-2-20210208","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","article-title":"Primary aldosteronism and hypertensive disease","volume":"42","author":"Mosso","year":"2003","journal-title":"Hypertension"},{"key":"R12-2-20210208","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjhyper.2005.01.002","article-title":"Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension","volume":"18","author":"Nishizaka","year":"2005","journal-title":"Am J Hypertens"},{"key":"R13-2-20210208","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1373\/clinchem.2004.041780","article-title":"Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity","volume":"51","author":"Schwartz","year":"2005","journal-title":"Clin Chem"},{"key":"R14-2-20210208","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R15-2-20210208","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/08037050600772615","article-title":"The prevalence of a raised aldosterone-renin ratio (ARR) among new referrals to a hypertension clinic","volume":"15","author":"Williams","year":"2006","journal-title":"Blood Press"},{"key":"R16-2-20210208","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1524-6175.2005.05251.x","article-title":"The prevalence of primary aldosteronism in diabetic patients","volume":"8","author":"Jefic","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R17-2-20210208","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.jhh.1001948","article-title":"Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalemia","volume":"20","author":"Williams","year":"2006","journal-title":"J Hum Hypertens"},{"key":"R18-2-20210208","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2337\/dc07-0031","article-title":"Primary aldosteronism in diabetic subjects with resistant hypertension","volume":"30","author":"Umpierrez","year":"2007","journal-title":"Diabetes Care"},{"key":"R19-2-20210208","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/02813430600830931","article-title":"High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden","volume":"24","author":"Westerdahl","year":"2006","journal-title":"Scand J Prim Healthcare"},{"key":"R20-2-20210208","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1291\/hypres.30.111","article-title":"Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone\/renin ratio above 25 as a screening test","volume":"30","author":"Fogari","year":"2007","journal-title":"Hypertens Res"},{"key":"R21-2-20210208","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/eje.0.1460523","article-title":"Primary aldosteronism in normokalemic patients with adrenal incidentalomas","volume":"146","author":"Bernini","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"R22-2-20210208","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1210\/jc.2003-032179","article-title":"Aldosterone to renin ratio in a primary care setting: the Bussolengo study","volume":"89","author":"Olivieri","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-2-20210208","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7861\/clinmedicine.5-1-55","article-title":"Prevalence of primary hyperaldosteronism assessed by aldosterone\/renin ratio and spironolactone testing","volume":"5","author":"Hood","year":"2005","journal-title":"Clin Med"},{"key":"R24-2-20210208","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1097\/01.hjh.0000187260.32567.75","article-title":"Primary hyperaldosteronism: a frequent cause of residual hypertension after successful endovascular treatment of renal artery disease","volume":"23","author":"Pizzolo","year":"2005","journal-title":"J Hypertens"},{"key":"R25-2-20210208","first-page":"17","article-title":"Normokalemic hyperaldosteronism in patients with resistant hypertension","volume":"4","author":"Benchetrit","year":"2002","journal-title":"Isr Med Assoc J"},{"key":"R26-2-20210208","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"R27-2-20210208","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","article-title":"Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study","volume":"371","author":"Douma","year":"2008","journal-title":"Lancet"},{"key":"R28-2-20210208","first-page":"220","article-title":"Aldosterone-to-renin ratio as a screening test for primary aldosteronism: the Dutch ARRAT Study","volume":"66","author":"Jansen","year":"2008","journal-title":"Neth J Med"},{"key":"R29-2-20210208","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"R30-2-20210208","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00004872-200201000-00017","article-title":"Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension","volume":"20","author":"Schlaich","year":"2002","journal-title":"J Hypertens"},{"key":"R32-2-20210208","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"key":"R33-2-20210208","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin\u2013angiotensin\u2013aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"R34-2-20210208","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"R35-2-20210208","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MNH.0b013e3282f56854","article-title":"Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation","volume":"17","author":"Young","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R36-2-20210208","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R37-2-20210208","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R38-2-20210208","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R39-2-20210208","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Intern Med"},{"key":"R40-2-20210208","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjhyper.2005.05.013","article-title":"Role of aldosterone in left ventricular hypertrophy in hypertension","volume":"19","author":"Matsumura","year":"2006","journal-title":"Am J Hypertens"},{"key":"R41-2-20210208","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.amjhyper.2006.02.002","article-title":"Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension","volume":"19","author":"Strauch","year":"2006","journal-title":"Am J Hypertens"},{"key":"R42-2-20210208","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.amjhyper.2004.08.026","article-title":"Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension","volume":"18","author":"Mahmud","year":"2005","journal-title":"Am J Hypertens"},{"key":"R43-2-20210208","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/cpt1978245525","article-title":"Antihypertensive responses to spironolactone in normal renin hypertension","volume":"24","author":"Ogilvie","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"R44-2-20210208","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0002-9149(76)90409-4","article-title":"Controlled treatment of primary hypertension with propranolol and spironolactone. A crossover study with special reference to initial plasma renin activity","volume":"37","author":"Karlberg","year":"1976","journal-title":"Am J Cardiol"},{"key":"R45-2-20210208","first-page":"31","article-title":"Comparison of chlorthalidone and spironolactone in low\u2013renin essential hypertension","volume":"128","author":"Kreeft","year":"1983","journal-title":"Can Med Assoc J"},{"key":"R46-2-20210208","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"key":"R47-2-20210208","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2125.1981.tb01271.x","article-title":"Comparison of single and divided daily dose spironolactone in the control of hypertension","volume":"12","author":"Bell","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"R48-2-20210208","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/hy1101.095010","article-title":"Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects","volume":"38","author":"Pratt","year":"2001","journal-title":"Hypertension"},{"key":"R49-2-20210208","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1046\/j.1523-1755.2000.00983.x","article-title":"Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology","volume":"57","author":"Delyani","year":"2000","journal-title":"Kidney Int"},{"key":"R50-2-20210208","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"R51-2-20210208","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","article-title":"Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension","volume":"25","author":"Burgess","year":"2003","journal-title":"Clin Ther"},{"key":"R52-2-20210208","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","article-title":"Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension","volume":"92","author":"White","year":"2003","journal-title":"Am J Cardiol"},{"key":"R53-2-20210208","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R54-2-20210208","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","article-title":"Effects of eplerenone versus losartan in patients with low-renin hypertension","volume":"150","author":"Weinberger","year":"2005","journal-title":"Am Heart J"},{"key":"R55-2-20210208","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","article-title":"Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension","volume":"93","author":"Williams","year":"2004","journal-title":"Am J Cardiol"},{"key":"R56-2-20210208","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension","volume":"41","author":"White","year":"2003","journal-title":"Hypertension"},{"key":"R57-2-20210208","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"R58-2-20210208","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3109\/10641969309037113","article-title":"The place of combination therapy in the treatment of hypertension in 1993","volume":"15","author":"Chalmers","year":"1993","journal-title":"Clin Exp Hypertens"},{"key":"R59-2-20210208","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"issue":"4","key":"R60-2-20210208","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","article-title":"The role of spironolactone in the treatment of patients with refractory hypertension","volume":"15","author":"Ouzan","year":"2002","journal-title":"Am J Hypertens"},{"issue":"11","key":"R61-2-20210208","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"R62-2-20210208","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.amjhyper.2005.11.016","article-title":"Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension","volume":"19","author":"Sharabi","year":"2006","journal-title":"Am J Hypertens"},{"key":"R63-2-20210208","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","article-title":"Low-dose spironolactone in the management of resistant hypertension: a surveillance study","volume":"25","author":"Lane","year":"2007","journal-title":"J Hypertens"},{"key":"R64-2-20210208","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","article-title":"Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension","volume":"46","author":"Saha","year":"2005","journal-title":"Hypertension"},{"key":"R65-2-20210208","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"R66-2-20210208","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"R67-2-20210208","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1097\/HJH.0b013e3282f254d9","article-title":"Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent","volume":"25","author":"Lane","year":"2007","journal-title":"J Hypertens"},{"key":"R68-2-20210208","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/10641960802441906","article-title":"Blood pressure-lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled blood pressure receiving hydrochlorothiazide","volume":"30","author":"Guerrero","year":"2008","journal-title":"Clin Exp Hypertens"},{"key":"R69-2-20210208","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/clpt.1980.75","article-title":"Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients","volume":"27","author":"Ramsay","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"R70-2-20210208","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin\u2013angiotensin\u2013aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R71-2-20210208","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/endo-118-2-819","article-title":"Intracerebroventricular infusion of aldosterone induces hypertension in rats","volume":"18","author":"Gomez-Sanchez","year":"1986","journal-title":"Endocrinology"},{"key":"R72-2-20210208","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0014-2999(01)01586-2","article-title":"Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension","volume":"436","author":"Rahmouni","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"R73-2-20210208","doi-asserted-by":"crossref","first-page":"H2241","DOI":"10.1152\/ajpheart.2001.281.5.H2241","article-title":"Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure","volume":"281","author":"Francis","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R74-2-20210208","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0735-1097(02)02855-3","article-title":"Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy","volume":"41","author":"Kasama","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R75-2-20210208","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1139\/y85-250","article-title":"Effect of aldosterone on vascular angiotensin II receptors in the rat","volume":"63","author":"Schiffrin","year":"1985","journal-title":"Can J Physiol Pharmacol"},{"issue":"4","key":"R76-2-20210208","first-page":"H608","article-title":"Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats","volume":"246","author":"Schiffrin","year":"1984","journal-title":"Am J Physiol"},{"key":"R77-2-20210208","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jcp.1041610203","article-title":"Mechanisms of enhanced angiotensin II-stimulated signal transduction in vascular smooth muscle by aldosterone","volume":"161","author":"Ullian","year":"1994","journal-title":"J Cell Physiol"},{"key":"R78-2-20210208","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/01.HYP.20.1.67","article-title":"Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses","volume":"20","author":"Ullian","year":"1992","journal-title":"Hypertension"},{"key":"R79-2-20210208","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0008-6363(96)00053-3","article-title":"Potentiation of angiotensin II action by corticosteroids in vascular tissue","volume":"32","author":"Ullian","year":"1996","journal-title":"Cardiovasc Res"},{"key":"R80-2-20210208","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1161\/01.HYP.0000182661.98259.4f","article-title":"Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II","volume":"46","author":"Chai","year":"2005","journal-title":"Hypertension"},{"issue":"1","key":"R81-2-20210208","doi-asserted-by":"crossref","first-page":"19S","DOI":"10.1016\/j.amjhyper.2004.10.001","article-title":"Role of arterial wall properties in the pathogenesis of systolic hypertension","volume":"18","author":"London","year":"2005","journal-title":"Am J Hypertens"},{"key":"R82-2-20210208","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/01.HYP.37.5.1236","article-title":"Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients","volume":"37","author":"Laurent","year":"2001","journal-title":"Hypertension"},{"key":"R83-2-20210208","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.107.690396","article-title":"The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone\u2013renin ratio","volume":"116","author":"Hood","year":"2007","journal-title":"Circulation"},{"key":"R84-2-20210208","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/01.HYP.0000023182.68420.EB","article-title":"Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism","volume":"40","author":"Rossi","year":"2002","journal-title":"Hypertension"},{"key":"R85-2-20210208","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.CIR.95.6.1471","article-title":"Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma","volume":"95","author":"Rossi","year":"1997","journal-title":"Circulation"},{"key":"R86-2-20210208","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"R87-2-20210208","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1253\/circj.69.1394","article-title":"Long-term effect of spironolactone on cardiac structure as assessed by analysis of ultrasonic radio-frequency signals in patients with ventricular hypertrophy","volume":"69","author":"Nishikawa","year":"2005","journal-title":"Circ J"},{"key":"R88-2-20210208","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1291\/hypres.25.837","article-title":"Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension","volume":"25","author":"Sato","year":"2002","journal-title":"Hypertens Res"},{"key":"R89-2-20210208","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1253\/circj.70.995","article-title":"Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy","volume":"70","author":"Taniguchi","year":"2006","journal-title":"Circ J"},{"key":"R90-2-20210208","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/147323000102900103","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy","volume":"29","author":"Sato","year":"2001","journal-title":"J Int Med Res"},{"key":"R91-2-20210208","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0735-1097(00)01129-3","article-title":"Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats","volume":"37","author":"Lacolley","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R92-2-20210208","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1161\/01.CIR.0000039328.33137.6C","article-title":"Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone","volume":"106","author":"Lacolley","year":"2002","journal-title":"Circulation"},{"key":"R93-2-20210208","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3317\/jraas.2006.004","article-title":"Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone","volume":"7","author":"Nehme","year":"2006","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R94-2-20210208","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1161\/01.HYP.0000128031.31572.a3","article-title":"Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats","volume":"43","author":"Endemann","year":"2004","journal-title":"Hypertension"},{"key":"R95-2-20210208","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1161\/HYPERTENSIONAHA.107.103267","article-title":"Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients","volume":"51","author":"Savoia","year":"2008","journal-title":"Hypertension"},{"key":"R96-2-20210208","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2125.2005.02363.x","article-title":"Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients","volume":"59","author":"Davies","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R97-2-20210208","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","article-title":"High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction","volume":"114","author":"Beygui","year":"2006","journal-title":"Circulation"},{"key":"R98-2-20210208","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000095671","article-title":"Raised plasma aldosterone and natriuretic peptides in atrial fibrillation","volume":"108","author":"Dixen","year":"2007","journal-title":"Cardiology"},{"key":"R99-2-20210208","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1742-1241.2006.00982.x","article-title":"QT interval is prolonged but QT dispersion is maintained in patients with primary aldosteronism","volume":"61","author":"Yang","year":"2007","journal-title":"Int J Clin Pract"},{"key":"R100-2-20210208","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.bjp.0706220","article-title":"Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?","volume":"145","author":"Chai","year":"2005","journal-title":"Br J Pharmacol"},{"key":"R101-2-20210208","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1161\/01.HYP.0000205831.39339.a5","article-title":"Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?","volume":"47","author":"Chai","year":"2006","journal-title":"Hypertension"},{"key":"R102-2-20210208","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1097\/HJH.0b013e3282e9a72d","article-title":"Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure","volume":"25","author":"Shah","year":"2007","journal-title":"J Hypertens"},{"key":"R103-2-20210208","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cardfail.2006.11.015","article-title":"Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure","volume":"13","author":"Gao","year":"2007","journal-title":"J Card Fail"},{"key":"R104-2-20210208","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","article-title":"Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias","volume":"111","author":"Ouvrard-Pascaud","year":"2005","journal-title":"Circulation"},{"key":"R105-2-20210208","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00210-006-0107-9","article-title":"Why are mineralocorticoid receptor antagonists cardioprotective?","volume":"374","author":"Chai","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R106-2-20210208","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabet Med"},{"key":"R107-2-20210208","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"R108-2-20210208","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"R109-2-20210208","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"R110-2-20210208","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"R111-2-20210208","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1681\/ASN.2004100878","article-title":"Relative glomerular hyperfiltration in primary aldosteronism","volume":"16","author":"Ribstein","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R112-2-20210208","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA"},{"key":"R113-2-20210208","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","article-title":"Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria","volume":"112","author":"Quinkler","year":"2005","journal-title":"Circulation"},{"key":"R114-2-20210208","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","article-title":"Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease","volume":"18","author":"Sato","year":"2005","journal-title":"Am J Hypertens"},{"key":"R115-2-20210208","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"R116-2-20210208","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/endo-97-1-52","article-title":"Antiandrogenic effect of spirolactones: mechanism of action","volume":"97","author":"Corvol","year":"1975","journal-title":"Endocrinology"},{"key":"R117-2-20210208","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/0003-4819-87-4-398","article-title":"Pathophysiology of spironolactone-induced gynecomastia","volume":"87","author":"Rose","year":"1977","journal-title":"Ann Intern Med"},{"key":"R118-2-20210208","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2265.2000.00982.x","article-title":"Spironolactone as a single agent for long-term therapy of hirsute patients","volume":"52","author":"Spritzer","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R119-2-20210208","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1210\/jc.2003-031780","article-title":"Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study","volume":"89","author":"Ganie","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R120-2-20210208","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-3083.2005.01072.x","article-title":"Effects and side-effects of spironolactone therapy in women with acne","volume":"19","author":"Yemisci","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R121-2-20210208","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1210\/jc.2003-032149","article-title":"Distinguishing the antihypertensive and electrolyte effects of eplerenone","volume":"89","author":"Levy","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R122-2-20210208","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ahj.2004.10.005","article-title":"Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure","volume":"148","author":"Tamirisa","year":"2004","journal-title":"Am Heart J"},{"key":"R123-2-20210208","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/bmj.38883.479549.2F","article-title":"Spironolactone and risk of upper gastrointestinal events: population based case\u2013control study","volume":"333","author":"Verhamme","year":"2006","journal-title":"BMJ"},{"issue":"12","key":"R124-2-20210208","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","article-title":"Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?","volume":"18","author":"Mahmud","year":"2005","journal-title":"Am J Hypertens"},{"key":"R125-2-20210208","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1177\/0091270003258189","article-title":"Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?","volume":"43","author":"Prisant","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R126-2-20210208","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/qjmed\/92.4.187","article-title":"The management of hypertensive disease in black patients","volume":"92","author":"Gibbs","year":"1999","journal-title":"Q J Med"},{"key":"R127-2-20210208","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","article-title":"Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study","volume":"48","author":"Lim","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R128-2-20210208","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.CIR.0000157146.86758.BC","article-title":"Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure","volume":"111","author":"Weintraub","year":"2005","journal-title":"Circulation"},{"key":"R129-2-20210208","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pcad.2006.02.002","article-title":"Use of aldosterone antagonists in resistant hypertension","volume":"48","author":"Calhoun","year":"2006","journal-title":"Prog Cardiovasc Dis"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004872-200904000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T02:02:49Z","timestamp":1618365769000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-200904000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":128,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e32832810ed","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}